English | Japanese
Company Investors Research News Contact us Careers


A privately held biopharmaceutical company based in Tokyo, Japan, Anaeropharma Science was established in 2004 to pioneer the development of novel therapeutics to target such a hypoxic environment in solid cancers based on its proprietary platform technology, recombinant bifidobacterium therapeutics. » Read full article

Latest News


We have updated Research Overview Page April 2nd, 2013

see here for detail.

Initiated First-in-Human Trial of Novel Recombinant Bifidobacterial Anti-cancer Agent APS001F for Advanced Solid Tumors April 2nd, 2013

We have initiated a Phase I clinical trial of APS001F in patients with advanced solid tumors in the United States. The first-in-human dose-escalation trial enrolls patients with advanced and/or metastatic solid tumors whose disease is no longer considered responsive to available treatments. The trial is designed to evaluate safety, tolerability and efficacy of the study agent.

more…

We have updated Research Overview page. June 22nd, 2012

see here for detail.

We have moved to our new office May 2nd, 2012

See here for detail.

INCJ determined on up to 2.2 billion yen follow-on investment February 21st, 2012

Innovation Network Corporation of Japan (INCJ) has determined on a follow-on investment of up to 2.2 billion yen in Anaeropharma.  INCJ has made its initial investment of 700 million yen in November 2010.

Introduced on Shinano Mainichi Shinbun January 27th, 2012

Anaeropharma’s technology was introduced on Shinano Mainich Shinbun.  December 31, 2011

We have moved to our new office April 26th, 2011
Fundraising of 700 million yen – capital contribution by INCJ November 25th, 2010

Anaeropharma has successfully completed closing of 700 million yen financing for its clinical trials. The investor – Innovation Network Corporation of Japan (INCJ) plans to continuously contribute to Anaeropharma’s future potential financing.

Tie-up with Eisai Co., Ltd. October 1st, 2010

Anaeropharma Science, Inc. and Eisai Co., Ltd.  have concluded an option agreement concerning APS001, a novel anticancer agent currently under development at Anaeropharma Science that utilizes characteristic features of Bifidobacterium longum, as well as an agreement concerning the discovery of novel anticancer agents that utilize Bifidobacterium as a drug delivery system.

more…

Introduced on Nikkei Business Daily January 8th, 2010

Anaeropharma’s Technology was introduced on Nikkei Business Daily.  November 30, 2009


Anaeropharma Science, Inc., ©2009- All rights reserved.